PET‐DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)

Le résumé fourni par la source

For analysis B, 1,887 (80%) of 2,338 patients were included who received 6x (45%) or 8x (55%) R-CHOP.Recipients of 6 cycles, as compared to recipients of 8 cycles, were older (median age, 71 v 61 years; P<0.001), whereas IPI score distribution was not significantly different (P = 0.099).The adjusted risk of mortality was similar between both groups across all age groups (Fig 1B for patients <65 years).Lastly, for analysis C, 897 (48%) of 1,887 patients were included, of whom most received 8x R-CHOP21 (49%) followed by 8x R-CHOP14 (26%), 6x R-CHOP21 (13%), and 6x R-CHOP14 (12%).Recipients of 6 R-CHOP21±2R, as compared to recipients of other regimens, were not older (median age, 55 v 55 years; P = 0.602), but had slightly less often an IPI of ≥3 (24% v 27%; P = 0.004).The adjusted risk of mortality was similar between 6xR-CHOP21±2R and the other regimens (Fig 1C).Conclusion: Our population-based analyses add support to the notion from several RCTs that R-CHOP21 and R-CHOP14, and 6x and 8x R-CHOP are equally effective.Furthermore, 6x R-CHOP21±2R was found to be equally effective compared to all other regimens in all age groups.Therefore, 6xR-CHOP21 (±2R) should be considered the preferred first-line regimen for all patients with advanced-stage DLBCL.The question whether 2R after 6x CHOP21 can be omitted without compromising efficacy remains a topic for future studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.